Vikas Lifecare

Who are the top shareholders of the Vikas Lifecare?

The top shareholders of Vikas Lifecare include promoter Vikas Garg with 13.1%, public shareholder Sylph Technologies at 3.1%, and individual investors holding 73.79%. There are also 18 Foreign Institutional Investors with a combined 0.46% stake, and no mutual funds currently hold shares.

The top shareholders of Vikas Lifecare include Vikas Garg, who is the promoter with the highest holding at 13.1%. The highest public shareholder is Sylph Technologies, holding 3.1%. Additionally, individual investors collectively hold a significant portion of the shares at 73.79%. The company also has 18 Foreign Institutional Investors (FIIs) with a combined holding of 0.46%. Notably, there are no mutual funds currently holding shares in the company.

how big is Vikas Lifecare?

As of Jun 06, Vikas Lifecare Ltd has a market capitalization of 473.71 Cr, with net sales of 480.02 Cr and a net profit of -10.14 Cr for the latest four quarters. Shareholder's funds are 476.69 Cr, and total assets amount to 554.70 Cr as of Mar'24.

Market Cap: As of Jun 06, Vikas Lifecare Ltd has a market capitalization of 473.71 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Vikas Lifecare reported net sales of 480.02 Cr and a net profit of -10.14 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: The balance sheet data is also on a Consolidated basis for the latest annual period ending in Mar'24. Shareholder's funds are reported at 476.69 Cr, while total assets amount to 554.70 Cr.

Has Vikas Lifecare declared dividend?

No Dividend History Available

Is Vikas Lifecare overvalued or undervalued?

As of July 22, 2024, Vikas Lifecare is considered overvalued and risky, with a negative PE ratio of -46.72 and an EV to EBITDA of -25.23, significantly underperforming against the Sensex with a year-to-date return of -38.77%.

As of 22 July 2024, the valuation grade for Vikas Lifecare has moved from very expensive to risky, indicating a significant shift in its market perception. The company is currently considered overvalued. Key ratios reveal a PE ratio of -46.72, an EV to EBITDA of -25.23, and a Price to Book Value of 0.89, which highlight the underlying financial challenges the company faces.<BR><BR>In comparison to its peers, Vikas Lifecare's valuation metrics are concerning, particularly when contrasted with industry standards. For instance, its PE ratio is significantly negative, while the EV to EBITDA ratio also reflects a troubling trend. Notably, the company has underperformed against the Sensex, with a year-to-date return of -38.77% compared to the Sensex's positive 5.56%. This performance further reinforces the notion that Vikas Lifecare is currently overvalued in the market.

What is the technical trend for Vikas Lifecare?

As of June 4, 2025, Vikas Lifecare's technical trend is bearish, supported by daily moving averages and Bollinger Bands, despite a mildly bullish weekly MACD, indicating a prevailing bearish market sentiment.

As of 4 June 2025, the technical trend for Vikas Lifecare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the daily moving averages and Bollinger Bands both signaling bearish trends. The weekly MACD shows a mildly bullish signal, but this is countered by the monthly MACD and KST both being bearish. The Dow Theory indicates a mildly bearish trend on the weekly timeframe, while the monthly shows no trend. Overall, the indicators suggest a prevailing bearish sentiment in the market for Vikas Lifecare.

Who are the peers of the Vikas Lifecare?

Vikas Lifecare's peers include Oswal Agro Mills, Veritas (India), and Mehai Technology, among others. Oswal Agro Mills and Mehai Technology show excellent management and growth, while Vikas Lifecare has a 1-year return of -50.39%, better than Veritas (India) but worse than Mehai Technology's 398.50%.

Peers: The peers of Vikas Lifecare are Oswal Agro Mills, Veritas (India), S T C, Mehai Technology, Kothari Products, Sakuma Exports, Riddhi Siddhi Gl, Balgopal Commer., and Northern Spirits.<BR><BR>Quality Snapshot: Excellent management risk is observed at Oswal Agro Mills and Mehai Technology, while Average management risk is found at Sakuma Exports, Riddhi Siddhi Gl, Balgopal Commer., and Northern Spirits, and the rest have Below Average management risk. Excellent growth is seen at Oswal Agro Mills and Mehai Technology, while Average growth is noted at Sakuma Exports, and the rest have Below Average growth. Excellent capital structure is present at Oswal Agro Mills and Veritas (India), while Good capital structure is found at Sakuma Exports and Balgopal Commer., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Mehai Technology at 398.50%, while Veritas (India) has the lowest at -66.05%. Vikas Lifecare's 1-year return is -50.39%, which is higher than Veritas (India) but lower than Mehai Technology. Additionally, the six-month return is negative for Veritas (India), Mehai Technology, Sakuma Exports, and Vikas Lifecare.

Who are in the management team of Vikas Lifecare?

As of March 2022, the management team of Vikas Lifecare includes Arvind Gupta (CFO), Anil Kumar, Ruby Bansal, Parul Rai (Company Secretary), Vijay Kumar Sharma (CEO), Sundeep Kumar Dhawan (Managing Director), Richa Sharma, and Chandan Kumar (CFO). Each member plays a key role in the company's governance and operations.

As of March 2022, the management team of Vikas Lifecare includes the following individuals:<BR><BR>1. Arvind Gupta - Director (Finance) & CFO<BR>2. Anil Kumar - Independent Director<BR>3. Ruby Bansal - Independent Director<BR>4. Parul Rai - Company Secretary & Compliance Officer<BR>5. Vijay Kumar Sharma - Director & Chief Executive Officer<BR>6. Sundeep Kumar Dhawan - Managing Director<BR>7. Richa Sharma - Independent Director<BR>8. Chandan Kumar - Director & CFO<BR><BR>Each member holds a specific role that contributes to the governance and operational management of the company.

What does Vikas Lifecare do?

Vikas Lifecare Ltd specializes in recycling plastic waste and manufacturing polymer compounds, operating within the Micro Cap market. As of March 2025, it reported net sales of 1,352 Cr and a net loss of 29 Cr, with a market cap of INR 479 Cr.

Overview:<BR>Vikas Lifecare Ltd operates in the recycling of plastic waste and the trading and manufacturing of polymer compounds, positioned in the Trading & Distributors industry within the Micro Cap market-cap bracket.<BR><BR>History:<BR>The company was originally incorporated as Vikas Multicorp Limited in 1995 and changed its name to Vikas Lifecare Limited on April 09, 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1,352 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: -29 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 479 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A (Loss Making)<BR>- Industry P/E: 19<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.13<BR>- Return on Equity: -1.91%<BR>- Price to Book: 0.89<BR><BR>Contact Details:<BR>- Address: G 1 34/1 East Punjabi Bagh, Vikas Apartments, New Delhi, Delhi: 110026<BR>- Tel: 91-011-40450110<BR>- Email: info@vikasmulticorp.com<BR>- Website: http://www.vikaslifecarelimited.com

Are Vikas Lifecare latest results good or bad?

Vikas Lifecare's latest results are disappointing, with a 23% decline in net sales to Rs 92.38 crore and a loss of Rs 3.96 crore in Profit After Tax, leading to a 'Strong Sell' rating by MarketsMOJO due to ongoing financial difficulties.

Vikas Lifecare's latest results are quite disappointing. For the quarter ending June 2025, the company reported net sales of Rs 92.38 crore, which is a significant decline of 23.0% compared to the average net sales of Rs 120.01 crore over the previous four quarters. This indicates a challenging sales environment.<BR><BR>Additionally, the company faced a loss of Rs 3.96 crore in Profit After Tax (PAT), which is a 56.2% decline from the average loss of Rs -2.54 crore in the prior four quarters. This trend suggests ongoing financial difficulties.<BR><BR>Moreover, interest expenses have increased by 36.03% over the preceding nine months, reaching Rs 4.04 crore, indicating higher borrowings that further complicate the financial situation. Overall, these results have led to a 'Strong Sell' rating by MarketsMOJO, reflecting a negative outlook for the company.

How has been the historical performance of Vikas Lifecare?

Vikas Lifecare has experienced fluctuating financial performance, with net sales increasing to 480.02 Cr in March 2025, but profitability declining significantly, resulting in a net loss of -10.61 Cr. Despite growth in total assets, cash flow from operations has worsened, indicating ongoing financial challenges.

Answer:<BR>The historical performance of Vikas Lifecare shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Vikas Lifecare's net sales have generally increased, reaching 480.02 Cr in March 2025 from 445.75 Cr in March 2024, although it slightly decreased from 476.05 Cr in March 2023. The total operating income followed a similar trend, peaking at 480.02 Cr in March 2025. However, the total expenditure has also risen, amounting to 501.62 Cr in March 2025, which has led to an operating profit (PBDIT) of 4.36 Cr, a decline from 30.49 Cr in the previous year. The company reported a profit before tax of -6.95 Cr in March 2025, down from 17.58 Cr in March 2024, resulting in a profit after tax of -5.00 Cr. The consolidated net profit also fell to -10.61 Cr in March 2025 from 14.03 Cr in March 2024. The total assets of Vikas Lifecare increased to 724.76 Cr in March 2025, up from 554.70 Cr in March 2024, while total liabilities rose to 724.76 Cr from 554.70 Cr in the same period. Cash flow from operating activities showed a negative trend, with -222.00 Cr in March 2025 compared to -41.00 Cr in March 2024, indicating challenges in cash generation. Overall, while Vikas Lifecare has seen growth in sales and assets, profitability has been inconsistent, reflecting a complex financial landscape.

When is the next results date for Vikas Lifecare Ltd?

The next results date for Vikas Lifecare Ltd is February 7, 2026.

The next results date for Vikas Lifecare Ltd is scheduled for February 7, 2026.

Should I buy, sell or hold Vikas Lifecare Ltd?

Why is Vikas Lifecare Ltd falling/rising?

As of 09-Mar, Vikas Lifecare Ltd's stock price is Rs 1.34, down 3.6%, reflecting a significant decline over various periods, including a 24.29% drop year-to-date and 58.13% over the past year. Weak fundamentals, lack of recent results, and poor financial performance have led to decreased investor confidence and a bearish trend.

As of 09-Mar, Vikas Lifecare Ltd's stock price is falling, currently at Rs 1.34, which reflects a decrease of Rs 0.05 or 3.6%. This decline is part of a broader trend, as the stock has underperformed significantly over various periods, including a 1-week drop of 4.29% and a 1-month decline of 17.79%. Year-to-date, the stock has decreased by 24.29%, and over the past year, it has plummeted by 58.13%, contrasting sharply with the Sensex, which has gained 4.35% in the same timeframe.<BR><BR>The company's weak long-term fundamentals contribute to the stock's poor performance. Notably, Vikas Lifecare has not declared results in the last six months, indicating a lack of transparency and potential financial instability. The company's ability to service its debt is also concerning, with a negative EBIT to Interest ratio of -0.77. Furthermore, the Return on Equity is low at 1.43%, suggesting minimal profitability relative to shareholders' funds.<BR><BR>Recent financial results have been disappointing, with net sales falling by 23.0% compared to the previous four-quarter average and a significant drop in profit after tax of 56.2%. Additionally, the stock is trading below all key moving averages, indicating a bearish trend. Although there has been a rise in investor participation, with a delivery volume increase of 30.45% on March 6, this has not translated into positive price movement.<BR><BR>Overall, the combination of weak financial performance, negative EBITDA, and a lack of recent results has led to a decline in investor confidence, contributing to the stock's falling price.

Which are the latest news on Vikas Lifecare?